 RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 GLOBE NEWSWIRE -- Liquidia Technologies, Inc. Nasdaq: LQDA, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:20am Eastern time. A link to the live audio webcast and replay of the presentation will be available on the Events Presentations page of the Companys corporate website, and will be archived for a minimum of 90 days.About LiquidiaLiquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension PAH and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit Contact InformationInvestor Relations: Jason Adair Vice President, Corporate Development and Strategy 919.328.4400 